News search

The team led by Dr. Pablo García-Pavía, based at the CNIC and Hospital Puerta de Hierro, has published the first study of a drug able to remove amyloid deposits from the heart

A CNIC study reveals that mutations previously identified in the gene MINDBOMB1 (MIB1) as causing non-compaction cardiomyopathy either provoke this disease or valve defects, depending on their combination with mutations in modifier genes

The findings, published in the Journal of the American College of Cardiology (JACC), will enable physicians to make appropriate treatment adjustments for patients with this disease

The findings, published in the Journal of the American College of Cardiology (JACC), represent a first step towards the personalized treatment of patients with this disease

A new study published in eLife shows that inhibition of p38γ/δ is a potential therapeutic strategy for the treatment of hypertrophic cardiomyopathy, but that this strategy has yet to be explored because of the lack of specific inhibitors for these p38 family members

Genetic screening combined with the detection of fibrosis identifies patients at risk of malignant arrhythmias or developing heart failure with severe complications

A team led by Dr. Jorge Alegre-Cebollada has shown, for the first time, an association between hypertrophic cardiomyopathy and mechanical alterations to a component of the contractile machinery of the heart

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Puerta de Hierro hospital in Majadahonda have found a possible treatment for this disease